Alzamend Neuro (ALZN) Change in Accured Expenses (2022 - 2026)

Alzamend Neuro has disclosed Change in Accured Expenses across 5 years of filings, most recently posting -$511176.0 for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 13674.62% year-over-year to -$511176.0; the TTM figure through Apr 2026 stood at $711391.0 (up 131.08% YoY), while the FY2026 annual figure was $711391.0, up 131.08% from the prior year.
• Change in Accured Expenses came in at -$511176.0 for Q2 2026 at Alzamend Neuro, down from $1.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q1 2023 to a low of -$1.6 million in Q4 2024.
• Average Change in Accured Expenses over 5 years is $11541.1, with a median of -$85383.0 recorded in 2023.
• Year-over-year, Change in Accured Expenses soared 939.23% in 2025 and sank 13674.62% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$378499.0 in 2022, then soared by 344.44% to $925202.0 in 2023, then slumped by 275.9% to -$1.6 million in 2024, then jumped by 83.67% to -$265823.0 in 2025, then slumped by 92.3% to -$511176.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$511176.0 in Q2 2026, $1.1 million in Q1 2026, and -$265823.0 in Q4 2025.